Stay updated on Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial
Sign up to get notified when there's something new on the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page.
Latest updates to the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page
- ChecktodayChange DetectedRevision tag updated from v3.3.3 to v3.3.4.SummaryDifference0.0%
- Check7 days agoChange DetectedA publication citation in the Publications section (Friedberg et al., Blood 2024) was added and subsequently removed; this does not affect the study design, endpoints, or eligibility. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedAdded a comprehensive Locations section listing U.S. states and Canadian provinces. Updated the page to Revision: v3.3.3 and removed the older v3.3.2 location blocks and the HHS Vulnerability Disclosure content.SummaryDifference2%
- Check51 days agoChange DetectedPublications section now indicates that entries are automatically filled from PubMed and updates the revision label to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check58 days agoChange DetectedRemoved the government funding lapse notice from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
- Check72 days agoChange DetectedNo significant additions or deletions were detected on the page between the two screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
Stay in the know with updates to Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page.